All News

Systemic anti-inflammatory treatments for PsO and PsA including methotrexate and biologics provided cardioprotective effects Potential cardiovascular benefits of IL-17i and IL-12/23i compared to TNFi @RheumNow #ACR23 Abs#0498 https://t.co/Np7PSNvFd6

#ACRBest @RheumNow https://t.co/u6DiQbebTF

Plenary 1 #ACR23 CVE in ARD/APS is a significant risk factor during pregnancies and the risk stays even after delivery for a significant amount of time. California based administrative data study! abst#722 @RheumNow https://t.co/HawhS4Gqko

Treatment intensification was associated with a higher ASDAS cut-off (2.7) value than the recommended one (≥2.1), the recommended cut-off could be too stringent or consider other factors than disease activity, Webers, El-Din Abst#0517 #ACR23 @RheumNow https://t.co/ZtBXhufxU1 https://t.co/MzvZQoFbvw

Should all of active moms with #SLE receive DVT prophylaxis post partum? High rates of VTE in #ARDs post partum #0722 #ACRbest #ACR23 @RheumNow @ACRheum Likely data driven by #SLE and maybe #RA and not all #autoimmune #rheumatic #disease. Large pop’n data from California https://t.co/sGJa5N6HUj

Plenary talk by Dhital etc al, shows increased risk of acute CV events in pregnant rheumatic, SLE, APS pts, esp if nephritis or APL+. #ACR23 Abstract 0722 https://t.co/pG0PqzVtIU

Analysis from the DESIR cohort reveal that pregnancy does not aggravate imaging changes in axSpA. Stat significant changes seen on Xray of LSIJ b4 & after delivery (p=0.037) but not worsening. Do these findings also translate to⬇️pain/improved QOL? #ACR23 ABST0513 @RheumNow https://t.co/s6xD2CaPwn

In a subgrp analysis of the SURPASS study by Dr @XBaraliakos et al, there was low spinal prog over 2 yrs in SEC & SDZ-ADL treated pts regardless of +/- Synd/⬆️CRP Synd+ > CRP+ as predictor of radiog prog Again, early dx = early tx #ACR23 ABST0522 @RheumNow https://t.co/fGF4szPJbp

Higher disease activity and systemic inflammation at baseline associated with greater risk of MACE in bDMARD nonusers but not in users. bDMARD-specific benefits directly on MACE risk beyond reducing inflammation, Karpouzas et al Abst#0391 #ACR23 @RheumNow https://t.co/lfoccZffTW https://t.co/ASpKYQof1I

Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy

Treatment of systemic juvenile idiopathic arthritis

Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc. AE trended higher in normal CRP pts taking Tofa compared to placebo @RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa

Long term safety data for bimekizumab (IL17i) in Psa & axSpA Overall as expected; increased infections (esp fungal/candida) & hepatic events No new signals... uveitis flares is interesting Need H2H of IL17's! IXE vs SEC vs BIM @RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA

Are anti CCP3 the new anti CCP2 antibodies? Not yet! Anti-CCP3 associated w/ diagnosis of RA in a population of patients w/ MSK symptoms But… very strong overlap between CCP2 and 3 with only 3.4% positive for CCP3 negative for CCP2 @RheumNow #ACR23 ABST 0389 https://t.co/BHRqCbqEYw

Detectable hs-cTnT at baseline was associated with future MACE HR 5.6, in the hsCRP high→low cohort with high inflammation at baseline, not vice versa. hs-cTnT may provide additional info for assessing CV risk, Weber et al, Abst#0387 https://t.co/M4zyz2tzIO #ACR23 @RheumNow https://t.co/omMgpRzBA5

Does pregnancy affect axSpA imaging? Large study of 381 pts, in the DESIR cohort, f/up of 5 years. Pregnancy did not aggravate imaging of axSpA women compared to prior to pregnancy. @RheumNow #ACR23 Abs#0513 https://t.co/eeGuxGGB5E

#ACR23 Abs 0465 suggests changes in rheums’ rx patterns in context of nationwide abortion restriction, particularly in abortion-restricted states; reproductive-age female pts may have less access to EB treatments like MTX/MMF for rheum dz. https://t.co/QN9C4PjUaN @rheumnow

Non invasive screening for pulmonary involvement in early RA Combination of PFT and Lung 🫁 US: -50% with interstitial or focal changes or pleural effusion on US -58% with abnormal DLCO Correlation w/ higher disease activity. Pathological meaning? @RheumNow ABST 0393 #ACR23 https://t.co/BBcOEgcJK2

@RheumNow PMR Mythbusters: we polled Aussie🇦🇺 rheumatologists How did those motivated enough to answer a PMR/GCA survey fare? Myth: PMR is only proximal - not bad Myth: PMR needs ⬆️ESR/CRP - a bit of work Time to #MakeRheumForPMR @victor_yang1 @CatherineL_Hill #ACR23 ABST0267 https://t.co/Z4ZkDHljOf https://t.co/ssHxOBJFxR

WEAR study: adherence to wearable activity trackers in RA Something that is consistent across all wearable studies is low adherence Here under 50% for PRO + tracking In an already selected population! To implement, we need to make this better? ABSTRACT 0344 @RheumNow #ACR23 https://t.co/csVZlzABGt

Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A

Topics

All News

Do you get our email newsletter?